[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 中华肝脏病杂志,2025,33(1):18-33. [2] 中华医学会消化病学分会. 中国肝硬化临床诊治共识意见[J]. 临床肝胆病杂志,2023,39(9):2057-2073. [3] 戴二黑,郭心如,王继涛,等. 肝硬化的病因及防治现状调查[J]. 中华医学杂志,2023,103(12):913-919. [4] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis [J]. Lancet, 2021, 398(10308): 1359-1376. [5] Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020 [J]. J Gastroenterol, 2021, 56(7): 593-619. [6] 刘茂萍,唐琳. 系统性红斑狼疮患者的肝脏受累研究进展[J]. 临床医学进展,2024,14(1):1228-1235. [7] Bessone F, Poles N, Roma M G. Challenge of liver disease in systemic lupus erythematosus: clues for diagnosis and hints for pathogenesis [J]. World J Hepatol, 2014, 6(6): 394-409. [8] Chowdhary V R, Crowson C S, Poterucha J J, et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients [J]. J Rheumatol, 2008, 35(11): 2159-2164. [9] 沈南,赵毅,段利华,等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志,2023,62(7):775-784. [10] 中华医学会血液学分会红细胞疾病(贫血)学组. Evans综合征诊断和治疗中国专家共识(2024年版)[J]. 中华血液学杂志,2024,45(9):809-815. [11] Hadzic N, Portmann B, Lewis I, et al. Coombs positive giant cell hepatitis--a new feature of Evans′ syndrome [J]. Arch Dis Child, 1998;78(4):397-398. [12] Audia S, Grienay N, Mounier M, et al. Evans syndrome: from diagnosis to treatment [J]. J Clin Med, 2020, 9(12): 3851. [13] Costallat G L, Appenzeller S, Costallat L T. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome [J]. Joint Bone Spine, 2012, 79(4):362-364. [14] Banko A, Cirkovic A, Miskovic R, et al. Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus [J]. Front Immuno, 2023,14:1307589. [15] Fattizzo B. Evans syndrome and infections: a dangerous cocktail to manage with caution [J]. Blood Transfus, 2021, 19(1): 5-8. [16] Zhang L, Wu X, Wang L, et al. Clinical features of systemic lupus erythematosus patients complicated with evans syndrome: a case-control, single center study [J]. Medicine (Baltimore), 2016, 95(15): e3279. [17] Adiga A, Nugent K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis) [J]. Am J Med Sci, 2017, 353(4): 329-335. [18] Hegazy A, Barakat A F, El Gayyar M A, et al. Prevalence and clinical significance of anti-C1q antibodies in cutaneous and systemic lupus erythematosus[J]. Egypt J Med Hum Genet, 2012, 13(2): 167-171. [19] 张奉春,周滨,董怡. 补体C1q及抗C1q抗体在狼疮肾炎发病机制中的作用[J]. 中华医学杂志,2005,85(14):955-959. [20] Trendelenburg M. Autoantibodies against complement component C1q in systemic lupus erythematosus [J]. Clin Transl Immunol, 2021, 10(4): e1279. [21] Zheng R H, Wang J H, Wang S B, et al. Clinical and immunopathological features of patients with lupus hepatitis [J]. Chin Med J (Engl), 2013, 126(2): 260-266. [22] Koscec M, Koren E, Wolfson-Reichlin M, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture [J]. J Immunol, 1997, 159(4): 2033-2041. [23] Arnett F C, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P [J]. Am J Med, 1995, 99(5): 465-472. [24] Calich A L, Viana V S, Cancado E, et al. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis [J]. Liver Int, 2013, 33(6): 909-913. [25] Ohira H, Takiguchi J, Rai T, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis [J]. Hepatol Res, 2004, 28(3): 137-139. [26] Fang X, Zaman M H, Guo X, et al. Role of hepatic deposited immunoglobulin G in the pathogenesis of liver damage in systemic lupus erythematosus [J]. Front Immunol, 2018, 9:1457. |